Eli Lilly will spend $3 billion expanding a recently acquired manufacturing facility in Wisconsin to provide capacity for injectable products, including its fast-growing obesity and diabetes drugs.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Aims to revolutionize pharmaceutical manufacturing with focus on advanced aseptic processing technology.

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Long-term growth is supported by new product launches, expanded manufacturing capacity, and a robust pipeline, positioning Eli Lilly for sustained success. On January 14th, Eli Lilly (NYSE ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli Lilly ...